Vimseltinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Investigating vimseltinib in tenosynovial giant cell tumors.
Journal: Expert opinion on pharmacotherapy
Published: January 25, 2026
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.
Journal: Pharmacological research
Published: January 20, 2026
Management of tenosynovial giant cell tumor: approved and investigational therapies.
Journal: Expert review of anticancer therapy
Published: January 20, 2026
Vimseltinib in non-resecable tenosynovial giant cell tumor
Journal: Bulletin du cancer
Published: December 04, 2025
Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT).
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: May 29, 2025
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma.
Journal: ESMO open
Published: May 21, 2025
Vimseltinib (Romvimza) for tenosynovial giant cell tumor.
Journal: The Medical letter on drugs and therapeutics
Published: April 20, 2025
Medical Management of Tenosynovial Giant Cell Tumor.
Journal: Current oncology reports
Published: April 15, 2025
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors.
Journal: Expert review of anticancer therapy
Published: February 27, 2025
Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs).
Journal: Intractable & rare diseases research
Published: February 19, 2025
Last Updated: 04/28/2026